普乐沙福（Mozobil）plerixafor

【Function and Indications】In combination with granulocyte colony stimulating factor (G-CSF): Mobilize hematopoietic stem cell collection and autologous transplantation in peripheral blood of patients with non-Hodgkin lymphoma and multiple myeloma.

【Model and Specification】20 mg/mL.

【Usage and Dosage】

After starting treatment with Mozobil, patients receive G-CSF once a day for 4 days.

Repeat Mozobil doses for up to 4 consecutive days.

Select a dose of 0.24 mg/kg actual body weight.

Administer by subcutaneous injection approximately 11 hours before the start of apheresis.

Renal impairment: If creatinine clearance ≤50 mL/min, reduce the dose by one-third to 0.16 mg/kg.

【Precautions】Not suitable for use in leukemia. May cause mobilization of tumor cells. Monitor blood and platelet counts (especially neutrophils). Monitor for spleen rupture (left upper abdominal/scapular or shoulder pain). Pregnancy (Cat.D); avoid.

[Adverse reactions and contraindications] Gastrointestinal discomfort, fatigue, injection site reactions, headache, joint pain, dizziness; tumor cell mobilization, increased circulating neutrophils, thrombocytopenia, splenomegaly, and vasovagal reactions may occur.

[Pregnant women use] Not recommended.

[Drug interactions] Drugs may enhance, reduce renal function, or compete for active tubular secretion.

[Manufacturer] Genzyme Corporation